Trials / Completed
CompletedNCT03280576
Validation of Progranulin as a Biomarker for Sepsis
Sensitivity and Specificity of Progranulin as a Biomarker for Sepsis
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 556 (actual)
- Sponsor
- Ludwig-Maximilians - University of Munich · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
Progranulin blood concentrations in patients with sepsis will be analysed in relation to disease status in order to validate progranulin as a biomarker for sepsis. Patients undergoing cardiac surgery will serve as controls.
Detailed description
Single nucleotide polymorphisms with known effects on Progranulin plasma concentrations will be assessed in a separate analysis. Expression levels of microRNAs isolated from plasma, circulating exosomes and blood cells will be determined by next-generation sequencing to characterize epigenetic influences on progranulin plasma levels.
Conditions
Timeline
- Start date
- 2015-04-01
- Primary completion
- 2019-04-01
- Completion
- 2019-06-01
- First posted
- 2017-09-12
- Last updated
- 2019-08-15
Locations
2 sites across 1 country: Germany
Source: ClinicalTrials.gov record NCT03280576. Inclusion in this directory is not an endorsement.